RxDoctor Payments Data

Vijaywant Brar, MD

Clinical Cardiac Electrophysiology · Shreveport, LANPI 1194166686

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (49.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 62.1% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $14,847 and has fallen 87.2% since, to $1,901 in 2025.

$25,122in general payments, 2019–2025

Across 250 payments — averaging $100.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$16K
  • Abbott$4K
  • Biotronik Inc.$1K
  • Medical Device Business Services, Inc.$1K
  • Biosense Webster, Inc.$807
  • Boston Scientific$799
  • plus $1K from 18 others

What the payments were for

  • Grants$12,50050%
  • Travel & lodging$4,96120%
  • Food & beverage$7,66130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,122 in reported general payments places this provider in the 55th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.

See all clinical cardiac electrophysiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$28,819
Medicare patients
238
Services billed
427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban152$115,344
EntrestoSacubitril/Valsartan12$24,168
MultaqDronedarone Hcl22$23,256
Dofetilide13$758
Mexiletine Hcl11$714
Amiodarone Hcl64$627
Metoprolol Succinate86$510
Diltiazem 24hr ErDiltiazem Hcl11$344
Midodrine Hcl11$325
Lisinopril13$124
Carvedilol33$112
Digoxin15$98
Furosemide12$73
Atorvastatin Calcium16$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$115,344152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.

Other clinical cardiac electrophysiology in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →